Compare AUDC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AUDC | ENGN |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | Israel | Canada |
| Employees | N/A | 82 |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 647.1M |
| IPO Year | 2000 | N/A |
| Metric | AUDC | ENGN |
|---|---|---|
| Price | $8.31 | $7.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.50 | ★ $21.00 |
| AVG Volume (30 Days) | 132.5K | ★ 521.9K |
| Earning Date | 05-05-2026 | 03-09-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $2.66 |
| 52 Week High | $11.48 | $12.25 |
| Indicator | AUDC | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 33.99 |
| Support Level | $8.13 | $6.18 |
| Resistance Level | $8.95 | $7.33 |
| Average True Range (ATR) | 0.24 | 0.64 |
| MACD | 0.09 | -0.10 |
| Stochastic Oscillator | 75.61 | 16.62 |
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.